These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 22770876)
1. Patterns of deregulation of insulin growth factor signalling pathway in paediatric and adult gastrointestinal stromal tumours. Italiano A; Chen J; Zhang L; Hajdu M; Singer S; DeMatteo RP; Antonescu CR Eur J Cancer; 2012 Nov; 48(17):3215-22. PubMed ID: 22770876 [TBL] [Abstract][Full Text] [Related]
2. Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA. Beadling C; Patterson J; Justusson E; Nelson D; Pantaleo MA; Hornick JL; Chacón M; Corless CL; Heinrich MC Cancer Med; 2013 Feb; 2(1):21-31. PubMed ID: 24133624 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Belinsky MG; Rink L; Flieder DB; Jahromi MS; Schiffman JD; Godwin AK; von Mehren M Genes Chromosomes Cancer; 2013 Feb; 52(2):214-24. PubMed ID: 23109135 [TBL] [Abstract][Full Text] [Related]
4. Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications. Lasota J; Wang Z; Kim SY; Helman L; Miettinen M Am J Surg Pathol; 2013 Jan; 37(1):114-9. PubMed ID: 22892600 [TBL] [Abstract][Full Text] [Related]
5. Insulin-like Growth Factor (IGF) system and gastrointestinal stromal tumours (GIST): present and future. Nannini M; Biasco G; Astolfi A; Urbini M; Pantaleo MA Histol Histopathol; 2014 Feb; 29(2):167-75. PubMed ID: 24129766 [TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Tarn C; Rink L; Merkel E; Flieder D; Pathak H; Koumbi D; Testa JR; Eisenberg B; von Mehren M; Godwin AK Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8387-92. PubMed ID: 18550829 [TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Pantaleo MA; Astolfi A; Di Battista M; Heinrich MC; Paterini P; Scotlandi K; Santini D; Catena F; Manara MC; Nannini M; Maleddu A; Saponara M; Lolli C; Formica S; Biasco G Int J Cancer; 2009 Dec; 125(12):2991-4. PubMed ID: 19672856 [TBL] [Abstract][Full Text] [Related]
9. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Janeway KA; Zhu MJ; Barretina J; Perez-Atayde A; Demetri GD; Fletcher JA Int J Cancer; 2010 Dec; 127(11):2718-22. PubMed ID: 20162573 [TBL] [Abstract][Full Text] [Related]
10. Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction. Nannini M; Astolfi A; Paterini P; Urbini M; Santini D; Catena F; Indio V; Casadio R; Pinna AD; Biasco G; Pantaleo MA Future Oncol; 2013 Jan; 9(1):121-6. PubMed ID: 23252569 [TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Braconi C; Bracci R; Bearzi I; Bianchi F; Sabato S; Mandolesi A; Belvederesi L; Cascinu S; Valeri N; Cellerino R Ann Oncol; 2008 Jul; 19(7):1293-1298. PubMed ID: 18372285 [TBL] [Abstract][Full Text] [Related]
12. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression. Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025 [TBL] [Abstract][Full Text] [Related]
13. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855 [TBL] [Abstract][Full Text] [Related]
14. Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients. Valadão M; Braggio D; Santos AF; Pimenta-Inada HK; Linhares E; Gonçalves R; Romano S; Vilhena B; Small I; Cubero D; Cruz F; Oliveira AT; Martinho O; Reis RM; Guimarães DP; Ferreira CG J Surg Res; 2012 Nov; 178(1):288-93. PubMed ID: 22516345 [TBL] [Abstract][Full Text] [Related]
15. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST). Nannini M; Biasco G; Astolfi A; Pantaleo MA J Med Genet; 2013 Oct; 50(10):653-61. PubMed ID: 23833252 [TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild-type gastrointestinal stromal tumours. Wong NA; Wingate J; Gradhand E Histopathology; 2015 Sep; 67(3):378-85. PubMed ID: 25659413 [TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor 2 targets IGF1R signaling transduction to facilitate metastasis and imatinib resistance in gastrointestinal stromal tumors. Li DG; Jiang JP; Chen FY; Wu W; Fu J; Wang GH; Li YB World J Gastrointest Oncol; 2024 Aug; 16(8):3585-3599. PubMed ID: 39171181 [TBL] [Abstract][Full Text] [Related]
20. Gene duplication, rather than epigenetic changes, drives FGF4 overexpression in KIT/PDGFRA/SDH/RAS-P WT GIST. Urbini M; Astolfi A; Indio V; Nannini M; Schipani A; Bacalini MG; Angelini S; Ravegnini G; Calice G; Del Gaudio M; Secchiero P; Ulivi P; Gruppioni E; Pantaleo MA Sci Rep; 2020 Nov; 10(1):19829. PubMed ID: 33199729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]